These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20579077)

  • 1. Novel VKORC1 mutations associated with warfarin sensitivity.
    Baniasadi S; Beizaee S; Kazemi B; Behzadnia N; Shafaghi B; Bandehpour M; Fahimi F
    Cardiovasc Ther; 2011 Aug; 29(4):e1-5. PubMed ID: 20579077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance.
    Ainle FN; Mumford A; Tallon E; McCarthy D; Murphy K
    Ir J Med Sci; 2008 Jun; 177(2):159-61. PubMed ID: 18266023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common VKORC1 and GGCX polymorphisms associated with warfarin dose.
    Wadelius M; Chen LY; Downes K; Ghori J; Hunt S; Eriksson N; Wallerman O; Melhus H; Wadelius C; Bentley D; Deloukas P
    Pharmacogenomics J; 2005; 5(4):262-70. PubMed ID: 15883587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records.
    Osman A; Enström C; Arbring K; Söderkvist P; Lindahl TL
    J Thromb Haemost; 2006 Aug; 4(8):1723-9. PubMed ID: 16879214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin K epoxide reductase complex subunit 1 (VKORC1 ) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study.
    Sconce EA; Avery PJ; Wynne HA; Kamali F
    J Thromb Haemost; 2008 Jul; 6(7):1226-8. PubMed ID: 18466315
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic basis of resistance to anticoagulants in rodents.
    Pelz HJ; Rost S; Hünerberg M; Fregin A; Heiberg AC; Baert K; MacNicoll AD; Prescott CV; Walker AS; Oldenburg J; Müller CR
    Genetics; 2005 Aug; 170(4):1839-47. PubMed ID: 15879509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
    Loriot MA; Beaune P
    Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
    Rost S; Fregin A; Ivaskevicius V; Conzelmann E; Hörtnagel K; Pelz HJ; Lappegard K; Seifried E; Scharrer I; Tuddenham EG; Müller CR; Strom TM; Oldenburg J
    Nature; 2004 Feb; 427(6974):537-41. PubMed ID: 14765194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.
    Fregin A; Czogalla KJ; Gansler J; Rost S; Taverna M; Watzka M; Bevans CG; Müller CR; Oldenburg J
    J Thromb Haemost; 2013 May; 11(5):872-80. PubMed ID: 23452238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.